This particular study19 scrutinized the oral and gut microbiota of melanoma patients undergoing PD‐1 therapy and found that patients with a healthy gut microbiota had significantly better anti‐tumor immunity than the control group, indicating the important role of immune therapy and patient's gut microbiota characteristics in the treatment of melanoma. The gene discussed is PDCD1; the disease is neoplasm.